Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081904941> ?p ?o ?g. }
- W3081904941 endingPage "119831" @default.
- W3081904941 startingPage "119831" @default.
- W3081904941 abstract "Posterior segment eye diseases affect more than 300 million patients worldwide resulting in severe visual impairment. The treatments available are invasive, costly, present irregular effectiveness, and cause serious adverse effects. These drawbacks significantly reduce patient compliance. In the last decade, solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) have shown potential as innovative carriers for lipophilic drug substances to overcome hurdles in treating the eye posterior segment. This review shows the advantages of these formulations, focusing on their compatibility with ocular tissues, which increases the internalization of the drug substances. Additionally, SLN and NLC can reduce the clearance by the eye's protective mechanisms due to adhesive properties related to nanometric size. Therefore, these preparations may allow the treating of several ophthalmic diseases by topical administration, increasing the interval between doses. This feature can decrease adverse effects and enhance efficacy, ultimately improving patient compliance. Thus, this critical review presents the performance of the in vitro, ex vivo, and in vivo assays that support the potential of SLN and NLC to treat diseases of the posterior segment of the eye. These nanoparticles have shown to be promising alternative towards a major shift in developing ophthalmic products." @default.
- W3081904941 created "2020-09-08" @default.
- W3081904941 creator A5020759071 @default.
- W3081904941 creator A5031825795 @default.
- W3081904941 creator A5035820937 @default.
- W3081904941 creator A5051362845 @default.
- W3081904941 creator A5061337632 @default.
- W3081904941 creator A5065179268 @default.
- W3081904941 creator A5076958181 @default.
- W3081904941 creator A5082557874 @default.
- W3081904941 date "2020-11-01" @default.
- W3081904941 modified "2023-10-03" @default.
- W3081904941 title "Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers" @default.
- W3081904941 cites W1193200159 @default.
- W3081904941 cites W1579046626 @default.
- W3081904941 cites W1925091978 @default.
- W3081904941 cites W1965106906 @default.
- W3081904941 cites W1969373623 @default.
- W3081904941 cites W1974689538 @default.
- W3081904941 cites W1975893269 @default.
- W3081904941 cites W1977755432 @default.
- W3081904941 cites W1986005500 @default.
- W3081904941 cites W2021658589 @default.
- W3081904941 cites W2021933371 @default.
- W3081904941 cites W2023792679 @default.
- W3081904941 cites W2031994679 @default.
- W3081904941 cites W2036358136 @default.
- W3081904941 cites W2040016102 @default.
- W3081904941 cites W2054189154 @default.
- W3081904941 cites W2055049428 @default.
- W3081904941 cites W2065991449 @default.
- W3081904941 cites W2071587107 @default.
- W3081904941 cites W2079141522 @default.
- W3081904941 cites W2079159055 @default.
- W3081904941 cites W2086106390 @default.
- W3081904941 cites W2093624389 @default.
- W3081904941 cites W2097158361 @default.
- W3081904941 cites W2098642477 @default.
- W3081904941 cites W2116413142 @default.
- W3081904941 cites W2117817142 @default.
- W3081904941 cites W2123215356 @default.
- W3081904941 cites W2142515257 @default.
- W3081904941 cites W2147842670 @default.
- W3081904941 cites W2160605010 @default.
- W3081904941 cites W2172610030 @default.
- W3081904941 cites W2208907383 @default.
- W3081904941 cites W225597385 @default.
- W3081904941 cites W2257984615 @default.
- W3081904941 cites W2333516128 @default.
- W3081904941 cites W2496476352 @default.
- W3081904941 cites W2511422297 @default.
- W3081904941 cites W2531244467 @default.
- W3081904941 cites W2535405793 @default.
- W3081904941 cites W2543988213 @default.
- W3081904941 cites W2551752956 @default.
- W3081904941 cites W2552524603 @default.
- W3081904941 cites W2567416294 @default.
- W3081904941 cites W2580175260 @default.
- W3081904941 cites W2588646316 @default.
- W3081904941 cites W2590312224 @default.
- W3081904941 cites W2603809109 @default.
- W3081904941 cites W2604905682 @default.
- W3081904941 cites W2606497583 @default.
- W3081904941 cites W2613202451 @default.
- W3081904941 cites W2620910292 @default.
- W3081904941 cites W2732877934 @default.
- W3081904941 cites W2735946885 @default.
- W3081904941 cites W2742080148 @default.
- W3081904941 cites W2748348718 @default.
- W3081904941 cites W2760728135 @default.
- W3081904941 cites W2761604622 @default.
- W3081904941 cites W2763459152 @default.
- W3081904941 cites W2800752654 @default.
- W3081904941 cites W2801128792 @default.
- W3081904941 cites W2805871338 @default.
- W3081904941 cites W2811076332 @default.
- W3081904941 cites W2892732274 @default.
- W3081904941 cites W2905574098 @default.
- W3081904941 cites W2912396451 @default.
- W3081904941 cites W2915230328 @default.
- W3081904941 cites W2919509863 @default.
- W3081904941 cites W2921685304 @default.
- W3081904941 cites W2924139370 @default.
- W3081904941 cites W2972053723 @default.
- W3081904941 cites W2982163613 @default.
- W3081904941 cites W3008785449 @default.
- W3081904941 cites W3015398915 @default.
- W3081904941 cites W3044166486 @default.
- W3081904941 cites W40231229 @default.
- W3081904941 cites W4211020962 @default.
- W3081904941 doi "https://doi.org/10.1016/j.ijpharm.2020.119831" @default.
- W3081904941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32877729" @default.
- W3081904941 hasPublicationYear "2020" @default.
- W3081904941 type Work @default.
- W3081904941 sameAs 3081904941 @default.
- W3081904941 citedByCount "28" @default.
- W3081904941 countsByYear W30819049412021 @default.
- W3081904941 countsByYear W30819049412022 @default.